Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Uruguay: These 6 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Uruguay: These 6 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can LASTACAFT (alcaftadine) generic drug versions launch in Uruguay?

Generic name: alcaftadine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 02, 2027
Generic Entry Controlled by: Uruguay Patent 30,254
Patent Title: TRATAMIENTOS PARA LA ALERGIA OCULAR

Drug Price Trends for LASTACAFT
LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. Additional details are available on the alcaftadine profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in Uruguay?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Uruguay Patent 30,319
Patent Title: FORMULACIONES DE INHIBIDORES DE DPP IV

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Uruguay?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Uruguay Patent 31,103
Patent Title: COMPOSICIONES FARMACEUTICAS EN BASE A MICROPARTICULAS COMPRENDIENDO UN ANALOGO DE SOMATOSTATINA, PROCESO DE PREPARACION Y APLICACIONES

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Uruguay?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Uruguay Patent 30,551
Patent Title: COMPOSICIONES FARMACÉUTICAS CONTENIENDO {1S-[1A(ALFA),2 A(ALFA), 3B(BETA)(1S*,2R*),5 B(BETA)]}-3-7-{[2-3,4-DIFLUOROFENIL)CICLOPROPIL]AMINO}-5-(PROPILITIO-3H-1,2,3-TRIAZOLO [4,5-D] PIRIMIDIN-3-Y 1-5-(2-HIDROXIETOXI)CICLOPENTANO-1,2-DIOL

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Uruguay?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Uruguay Patent 30,761
Patent Title: DERIVADOS DE 2.3-DIHIDROIMIDAZO(1,2-C) QUINAZOLINA SUSTITUIDA UTILES PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS HIPER-PROLIFERATIVOS ASOCIADOS CON LA ANGIOGÉNESIS

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Uruguay?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Uruguay Patent 30,762
Patent Title: SAL FUMARATO DE (ALFA S, BETA R)-6-BROMO-ALFA-[2(DIMETILAMINO) ETIL]-2-METOXI-ALFA-1-NAFTALENIL-BETA-FENIL-3-QUINOLINAETANOL

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

Last updated: October 10, 2026

Uruguay’s pharmaceutical market is small, import-dependent and institutionally concentrated. Commercial opportunity is strongest in branded generics, complex generics, biosimilars, specialty medicines and products supplied through public tenders or private mutualista networks. Regulatory access is comparatively manageable, but price competition, institutional purchasing power, local registration requirements and limited market scale constrain returns. Uruguay has no U.S.-style Orange Book, no routine Paragraph IV system and no established patent-linkage mechanism connecting marketing authorization to patent status.

Uruguay Branded and Generic Drug Market Assessment: Regulation, Patents and Commercial Opportunities

Uruguay has a population of approximately 3.5 million and a mature healthcare system divided between the public provider Administración de los Servicios de Salud del Estado, private mutualistas and commercial pharmacies. The market has high urban concentration, broad health coverage and a relatively sophisticated prescriber and payer base.

Local pharmaceutical production exists, but Uruguay remains dependent on imported active pharmaceutical ingredients, finished products, biologics and specialized manufacturing technologies. Local companies compete with multinational affiliates and regional suppliers through branded generics, tender participation, licensing and contract manufacturing.

What is the structure of Uruguay’s branded and generic drug market?

Uruguay’s market has four commercially relevant segments:

Segment Main buyers Commercial characteristics
Originator brands Mutualistas, private hospitals, specialists, pharmacies Higher prices, concentrated in patented, specialty and hospital products
Branded generics Mutualistas, pharmacies, prescribers Core local-market segment; brand reputation and supply reliability matter
Unbranded or low-price generics Public institutions, tenders, price-sensitive patients Strong price pressure and limited brand differentiation
Specialty and high-cost medicines FNR, hospitals, mutualistas and public programs Access depends on reimbursement, clinical criteria and budget controls

Uruguay’s private healthcare institutions are major pharmaceutical purchasers. A product may obtain regulatory approval but still fail commercially if it is not included in institutional formularies or cannot compete in procurement processes.

Local manufacturers and distributors commonly compete through:

  • Brand recognition among physicians and pharmacists.
  • Institutional tender pricing.
  • Local packaging and distribution capacity.
  • Licensing of foreign products.
  • Regional manufacturing and export platforms.
  • Registration portfolios covering multiple strengths and dosage forms.

The market is less attractive for undifferentiated oral solid products where several suppliers already compete. It is more attractive for products with supply shortages, limited competition, specialized delivery systems, difficult-to-source APIs or strong institutional demand.

Which companies compete in Uruguay’s pharmaceutical market?

Competition includes local laboratories, regional manufacturers and multinational companies operating through subsidiaries, distributors or licensing arrangements. Uruguay has a recognized domestic manufacturing base, although the size of individual companies and product-specific market shares varies by therapeutic area.

Relevant competitive groups include:

  • Uruguayan manufacturers producing branded generics and prescription medicines.
  • Regional Latin American laboratories supplying finished products.
  • Multinational pharmaceutical companies with originator and specialty portfolios.
  • Contract manufacturers and importers.
  • Distributors serving pharmacies, hospitals and mutualistas.

Examples of established local or locally active pharmaceutical companies include Urufarma, Laboratorio Roemmers Uruguay, Spefar and Adium-linked operations. The competitive relevance of each company differs by therapeutic category, procurement channel and product registration.

A foreign entrant usually needs a local regulatory and commercial structure. Options include appointing a local representative, licensing a product to an established laboratory, using a local importer or creating a Uruguayan affiliate.

What is Uruguay’s FDA regulatory status for medicines?

Uruguay does not have an agency named the FDA. Pharmaceutical regulation is administered primarily by the Ministry of Public Health, or Ministerio de Salud Pública, through its medicines and health-product authorities.

The principal regulatory functions include:

  • Marketing authorization and product registration.
  • Manufacturing and import controls.
  • Good manufacturing practice oversight.
  • Labeling and packaging requirements.
  • Pharmacovigilance.
  • Advertising and promotional controls.
  • Inspection of manufacturers, importers and distributors.
  • Control of controlled substances and special medicines.

Uruguay’s core medicines framework derives from Law No. 15.443 and related regulations. The Ministry of Public Health maintains administrative procedures and technical requirements for pharmaceutical products, while national law applies to registration, manufacturing, distribution and use.[1]

How long does medicine registration take in Uruguay?

Timing depends on product type, dossier completeness, manufacturing-site status, local representative arrangements and whether the product requires additional clinical, bioequivalence or quality review.

In practice, applicants should expect the following risk factors:

Regulatory factor Impact on approval
Incomplete administrative dossier Requests for correction and delay
Foreign manufacturing site Additional documentation and inspection requirements
New active ingredient More extensive clinical and safety review
Generic product Bioequivalence and quality documentation may be required
Biologic or biosimilar Complex comparability and manufacturing review
Controlled medicine Additional permissions and traceability requirements
Local labeling deficiencies Regulatory hold or rejection

Approval planning should treat registration as a dossier-management project rather than a single filing event. Certificates of pharmaceutical product, GMP evidence, manufacturing records, stability data, labeling translations and legalized documents can materially affect timing.

What patents protect medicines in Uruguay?

Uruguay grants pharmaceutical patents under Law No. 17.164, which implemented the country’s modern patent framework and the obligations associated with the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights.[2][3]

The principal protection periods are:

Right General term
Product or process patent 20 years from the filing date
Pharmaceutical composition patent Generally 20 years from filing
Manufacturing-process patent Generally 20 years from filing
Formulation patent Generally 20 years from filing
Use or treatment-related claim Depends on claim scope and patentability
Supplementary protection Not generally equivalent to the EU SPC system

Patent enforceability depends on claim scope, validity, ownership, maintenance fees, territorial coverage and evidence of infringement. A patent filed in the United States, Europe or Brazil does not automatically protect the same product in Uruguay. Uruguay requires a national patent or a valid international filing entering the Uruguayan system.

How strong is the patent estate for medicines sold in Uruguay?

Patent strength is generally strongest where a product has:

  • A granted compound patent with meaningful remaining term.
  • Valid formulation or dosage-form claims.
  • Manufacturing-process claims that are difficult to design around.
  • Multiple patents covering different technical layers.
  • A strong regulatory and clinical data position.
  • Institutional or specialist demand that supports premium pricing.

Patent strength is weaker where:

  • The compound patent has expired.
  • Only narrow formulation claims remain.
  • The product has several technically simple alternatives.
  • The patent has not been validated or maintained locally.
  • Generic manufacturers can use a different process or formulation.
  • Market access depends mainly on price.

Patent searches should cover the Uruguayan Patent Office, WIPO PATENTSCOPE and international family records. The relevant analysis must distinguish between an international patent family and an enforceable Uruguayan right.[4]

Does Uruguay have an Orange Book or Paragraph IV system?

Uruguay does not maintain an Orange Book equivalent that systematically lists patents associated with approved medicines. It also does not operate a U.S.-style Paragraph IV certification process.

A generic applicant generally does not use a formal Paragraph IV declaration to challenge a listed patent. Patent disputes are handled through ordinary civil and commercial enforcement mechanisms rather than through a dedicated Hatch-Waxman litigation pathway.

This creates two practical consequences:

  1. Regulatory approval and patent clearance are separate workstreams.
  2. A generic may be able to obtain registration without the regulator deciding whether commercial launch would infringe a patent.

The absence of patent linkage reduces administrative barriers to registration but does not eliminate launch risk. A patent owner can still seek judicial relief, including injunctions or damages, if it establishes infringement.

When do branded medicines lose exclusivity in Uruguay?

Exclusivity usually erodes through a combination of patent expiry, loss of market exclusivity in other jurisdictions, generic registration and institutional substitution.

Uruguay does not generally provide a U.S.-style five-year new chemical entity exclusivity period or a centralized, product-specific exclusivity register comparable to the FDA’s regulatory exclusivity listings. Protection must therefore be analyzed across several legal and commercial layers:

Protection layer Relevance in Uruguay
Compound patent Primary protection for the active ingredient
Process patent May restrict a particular manufacturing route
Formulation patent May protect release profile, excipients or dosage form
Use patent May protect a defined indication or regimen
Regulatory data May have limited practical relevance compared with patent rights
Trademark Protects branding but not the active ingredient
Trade secrets Important for manufacturing and technical know-how
Institutional contracts Can affect access without creating exclusivity

A product may remain commercially strong after patent expiry if it has prescriber loyalty, a trusted brand, supply reliability or a protected delivery system. Conversely, a product may face immediate price erosion if several registered competitors enter at the same time.

What formulation patents protect in Uruguay?

Formulation patents can protect technical features that remain commercially relevant after compound-patent expiry. Common categories include:

  • Extended-release tablets.
  • Enteric-coated products.
  • Fixed-dose combinations.
  • Injectable depot systems.
  • Specific excipient combinations.
  • Particle-size or polymorph characteristics.
  • Transdermal delivery systems.
  • Ophthalmic formulations.
  • Pediatric dosage forms.
  • Stability-enhancing compositions.

The commercial value of a formulation patent depends on whether the generic can design around the claim while maintaining therapeutic equivalence. A narrow excipient claim may have limited market impact if alternative formulations are available. A broad, technically difficult delivery-system claim can create a more meaningful barrier.

What method-of-use patents affect generic entry?

Method-of-use patents may cover:

  • A particular indication.
  • Patient selection.
  • Dosing schedules.
  • Combination therapy.
  • Biomarker-defined treatment.
  • Sequencing with another medicine.
  • Prevention of a defined clinical event.

Uruguay does not provide a standardized U.S.-style skinny-label framework that automatically resolves every use-patent issue. Generic applicants and patent owners must assess claim scope, labeling, promotion, physician prescribing behavior and potential contributory infringement theories.

A generic may reduce risk by omitting a patented indication from its proposed labeling, but the practical effectiveness of that strategy depends on the patent wording, regulatory approval and actual commercial conduct.

What patent litigation affects the Uruguayan pharmaceutical market?

Uruguay does not publish a centralized database equivalent to U.S. Hatch-Waxman litigation records. Public information on pharmaceutical patent disputes, settlements and product-specific injunctions is therefore less standardized.

The main litigation risks are:

  • Patent infringement claims against a local manufacturer or importer.
  • Challenges to patent validity.
  • Disputes over ownership or assignment.
  • Preliminary injunction applications.
  • Trademark disputes involving generic branding.
  • Regulatory or customs actions connected to alleged infringement.
  • Contract disputes involving licenses or distribution rights.

There is no established public record of a broad, recurring Uruguay-specific pattern of branded-generic settlement agreements comparable to U.S. pharmaceutical settlements. Licensing and commercial arrangements are more likely to be negotiated privately.

What licensing deals are common in Uruguay?

Licensing is a central market-entry route. Typical structures include:

Deal type Typical purpose
Exclusive commercial license Local sales and registration by one partner
Nonexclusive distribution Supply through several channels
Technology-transfer agreement Local manufacture or packaging
Registration transfer Change of local marketing authorization holder
Co-marketing agreement Shared brand or separate branded products
Regional license Uruguay combined with Mercosur or Latin American territories
Contract manufacturing Local production without full ownership of the brand

Key diligence points include ownership of the marketing authorization, responsibility for pharmacovigilance, recall obligations, supply continuity, minimum purchase volumes, price approvals, tender participation and control of regulatory variations.

A foreign company should avoid granting a license without defining who controls the registration dossier after termination. The local marketing authorization and regulatory file can have material commercial value.

What is the generic and biosimilar risk in Uruguay?

Generic risk is highest for small-molecule medicines with:

  • Expired or weak patent protection.
  • High prescription volume.
  • Simple oral dosage forms.
  • Multiple existing registrations.
  • Institutional tender demand.
  • Low manufacturing complexity.

Biosimilar risk is more selective. Biologics require greater investment in cell lines, analytical characterization, process control, comparability studies and manufacturing capacity. That raises barriers to entry but does not eliminate competition.

Potential biosimilar opportunity exists in:

  • Monoclonal antibodies.
  • Insulins.
  • Erythropoietins.
  • Filgrastim and related products.
  • Hospital-administered biologics.
  • High-cost products subject to centralized reimbursement controls.

Biosimilar commercial success depends less on pharmacy substitution than on hospital protocols, specialist acceptance, procurement decisions and reimbursement policy. Interchangeability and substitution should be assessed product by product under Ministry of Public Health requirements rather than assumed from approval alone.

How does public procurement affect drug prices in Uruguay?

Public and institutional procurement can determine market access. ASSE, public hospitals, mutualistas and high-cost treatment programs may use tenders, formularies, framework arrangements or negotiated purchasing.

Price pressure is strongest where:

  • Several products are therapeutically substitutable.
  • The buyer purchases large institutional volumes.
  • Supply continuity is measurable.
  • A product has no meaningful patent or formulation differentiation.
  • The product is included in a high-cost treatment program with budget controls.

A supplier must model tender economics separately from retail pharmacy economics. The lowest registered price does not always produce the strongest position if the supplier cannot guarantee delivery, manage recalls or meet local packaging and documentation requirements.

What are the main regulatory opportunities in Uruguay?

The most credible opportunities are:

Branded generic expansion

Local prescriber familiarity and pharmacy access support branded generics, particularly where product quality, supply and physician promotion are consistent.

Specialty medicines

Products for oncology, immunology, rare diseases and hospital use can command higher revenue per patient, but reimbursement and institutional access are decisive.

Biosimilars

The market offers a platform for companies with robust analytical and manufacturing capabilities, especially where originator prices create payer pressure.

Local manufacturing and regional supply

Uruguay can support regional packaging, manufacturing or distribution strategies, particularly for companies seeking a Mercosur-oriented operating model.

Contract registration and licensing

Companies without a local affiliate can enter through established laboratories that already have regulatory infrastructure, sales teams and institutional relationships.

Shortage and supply-reliability products

Products with recurrent availability problems can gain share if a supplier offers reliable inventory and rapid regulatory maintenance.

What are the main regulatory and commercial challenges?

The principal challenges are:

  • Small absolute market size.
  • High concentration of institutional purchasing.
  • Limited price tolerance for standard generics.
  • Dependence on imported APIs and finished products.
  • Local registration and document legalization requirements.
  • Complex access pathways for high-cost medicines.
  • Limited transparency compared with the U.S. patent and regulatory systems.
  • Potential exposure to currency, import and tender volatility.
  • Need for local pharmacovigilance and post-market compliance.
  • Difficulty recovering investment in products with low patient volume.

A product can be legally registrable but commercially unattractive. Registration costs, stability studies, artwork, pharmacovigilance and local distribution expenses must be compared with expected annual volume.

How does Uruguay compare with Brazil and Argentina?

Factor Uruguay Brazil Argentina
Market size Small Very large Large
Regulatory complexity Moderate High Moderate to high
Institutional purchasing power High relative to market size Very high High but volatile
Generic competition Strong Very strong Strong
Patent-linkage model No U.S.-style Orange Book No direct U.S. equivalent No direct U.S. equivalent
Local manufacturing importance Material but limited in scale Very high High
Regional entry value Distribution and pilot market Major standalone market Major standalone market
Pricing environment Competitive Highly competitive Inflation and currency-sensitive
Biosimilar opportunity Selective Broad Broad but economically variable

Uruguay is better suited to controlled market entry, regional registration strategy, specialized products and partnership models than to volume-led commodity generic launches.

What is the likely revenue exposure for originator companies?

Revenue exposure after generic entry depends on product class:

Product type Expected erosion risk after competition
Simple immediate-release tablet High
Branded chronic-care medicine Moderate to high
Complex injectable Moderate
Device-linked or delivery-system product Low to moderate
Hospital biologic Moderate, depending on procurement
Rare-disease medicine Lower volume risk but high reimbursement risk
Fixed-dose combination with formulation protection Variable

Originator companies should quantify exposure by channel rather than by national sales alone. Pharmacy sales, mutualista supply, hospital procurement and high-cost reimbursement can experience different pricing and substitution patterns.

Key Takeaways

  • Uruguay is a small but regulated pharmaceutical market with strong institutional purchasing.
  • Branded generics dominate much of the commercial opportunity.
  • The country has no U.S.-style Orange Book or Paragraph IV process.
  • Patent protection generally runs for 20 years from filing under Law No. 17.164.
  • Compound, formulation, process and method-of-use patents must be assessed separately.
  • Generic registration and patent clearance are distinct issues.
  • Biosimilar opportunity exists but depends on analytical capability, reimbursement and specialist adoption.
  • Local licensing, distribution and contract manufacturing are practical entry models.
  • Public and mutualista procurement can determine commercial success more than retail demand.
  • The strongest opportunities are specialty medicines, complex generics, biosimilars, shortage products and regionally scalable manufacturing.

FAQs About Uruguay’s Pharmaceutical Market

Can a generic medicine be registered in Uruguay before a patent expires?

Regulatory registration and patent enforcement are separate questions. A generic may pursue regulatory approval, but commercial launch remains subject to enforceable Uruguayan patent rights.

Does Uruguay recognize U.S. FDA approval for a drug?

FDA approval can support the technical dossier, but it does not replace Uruguayan marketing authorization. The Ministry of Public Health applies its own registration and compliance requirements.

Are biosimilars automatically interchangeable in Uruguay?

No automatic assumption should be made. Interchangeability and substitution depend on the product, regulatory determination, clinical context and institutional practice.

Is local manufacturing required to sell medicines in Uruguay?

No. Imported medicines can be marketed through an authorized local representative or importer, subject to registration, quality, labeling and distribution requirements.

Can a pharmaceutical company use Uruguay as a Mercosur registration hub?

Uruguay can support regional licensing, packaging and distribution strategies, but approval in Uruguay does not automatically grant marketing authorization in Brazil, Argentina or other Mercosur markets.

References

  1. Ministerio de Salud Pública de Uruguay. (n.d.). Medicamentos y productos farmacéuticos. Government of Uruguay.

  2. Uruguay. (1999). Law No. 17.164: Patents of invention, utility models and industrial designs. Diario Oficial.

  3. World Trade Organization. (1994). Agreement on Trade-Related Aspects of Intellectual Property Rights. WTO.

  4. World Intellectual Property Organization. (n.d.). PATENTSCOPE: International patent search. WIPO.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.